J&J is also running mid-stage trials of a tau active immunotherapy codenamed JNJ-2056 for Alzheimer's, while other active tau ...

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. | Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease ...

Days after Johnson & Johnson’s posdinemab failed to slow clinical decline in patients with Alzheimer’s disease, Eisai Chief ...

There have been some interesting failures recently in Alzheimer’s trials. Two are notable because they’re aimed outside the ...

Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau ...

Research shows the p-tau217 blood test can indicate very high risk of Alzheimer's disease before symptoms begin, offering ...

The outlook for dementia care is changing fast. UC experts explain what that means for patients and families, and what it ...

Alzheimer's disease (AD) is a neurodegenerative condition characterized by the progressive deterioration of brain cells, ...

Scientists have uncovered a surprising mechanism by which a brain enzyme called OTULIN controls the expression of tau, the ...

A new review highlights five major ways microplastics can harm the brain, raising concerns that they may worsen ...

Alzheimer’s disease is the most commonly diagnosed form of dementia, but it’s far from the only one. In fact, most people who ...